Expertise in
54
conditions

Dr. Thomas M. Fynan

Oncology
Hillcrest Hospital
165 Tor Ct, 
Pittsfield, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
54
conditions
Hillcrest Hospital
165 Tor Ct, 
Pittsfield, MA 

Overview

Thomas Fynan is an Oncologist practicing medicine in Pittsfield, Massachusetts.

Dr. Fynan is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CT

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Hillcrest Hospital
165 Tor Ct, Pittsfield, MA 01201
Other Locations
Office
2080 Whitney Ave Ste 240, Hamden, CT 06518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Trastuzumab, Pertuzumab
Study Phase: Phase 1
View 5 Less Clinical Trials

1 Total Publications

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: December 11, 2017
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Amc

47 New Scotland Ave, 
Albany, NY 
 (28.5 miles away)
518-262-5226
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Weaver is an Oncologist practicing medicine in Albany, New York. Dr. Weaver is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Oligodendroglioma, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Glioblastoma.

Expertise in
32
conditions
Dr. Heidi E. Godoy
Oncology | Obstetrics and Gynecology
Expertise in
32
conditions
Dr. Heidi E. Godoy
Oncology | Obstetrics and Gynecology
Referral may be required

New York Oncology Hematology PC

400 Patroon Creek Blvd, Ste 211, 
Albany, NY 
 (30.8 miles away)
518-801-0725
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heidi Godoy is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Albany, New York. Dr. Godoy is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery. Dr. Godoy is board certified in American Board Of Obstetrics And Gynecology Subspecialty, Gynecologic Oncology and American Board Of Obstetrics & Gynecology, Obstetrics And Gynecology. Dr. Godoy is currently accepting new patients.

Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Collaborative Laboratory Services-Mount Sinai Campus

114 Woodland St, 
Hartford, CT 
 (55.9 miles away)
860-714-4680
Languages Spoken:
English
See accepted insurances

James Vredenburgh is an Oncologist practicing medicine in Hartford, Connecticut. Dr. Vredenburgh is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, Lung Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Thomas M. Fynan

How do I make an appointment with Dr. Thomas M. Fynan?

You can book an appointment with Dr. Thomas M. Fynan by calling their office at 413-443-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas M. Fynan a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas M. Fynan is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas M. Fynan specialize in?

While Dr. Thomas M. Fynan is a Oncology, they have specific expertise in Paget Disease of the Breast, Angiosarcoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Thomas M. Fynan participate in research or clinical trials?

Yes. Dr. Thomas M. Fynan has published 1 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Thomas M. Fynan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas M. Fynan accept my insurance?

Dr. Thomas M. Fynan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 413-443-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fynan's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile